Articles published by Regeneron Pharmaceuticals, Inc.Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Via GlobeNewswire
Tickers
REGN
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
Via GlobeNewswire
Tickers
REGN
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
Via GlobeNewswire
Tickers
REGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|